Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s00415-021-10910-1.pdf
Reference43 articles.
1. Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H (2017) Benefit-risk profile of Sphingosine-1-Phosphate receptor modulators in relapsing and secondary progressive multiple sclerosis. Drugs 77(16):1755–1768. https://doi.org/10.1007/s40265-017-0814-1 (PMID: 28905255; PMCID: PMC5661009)
2. Chaudhry BZ, Cohen JA, Conway DS (2017) Sphingosine 1-Phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 14(4):859–873. https://doi.org/10.1007/s13311-017-0565-4 (PMID: 28812220; PMCID: PMC5722770)
3. Subei AM, Cohen JA (2015) Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 29(7):565–575. https://doi.org/10.1007/s40263-015-0261-z (PMID: 26239599; PMCID: PMC4554772)
4. Sharma S, Mathur AG, Pradhan S, Singh DB, Gupta S (2011) Fingolimod (FTY720): first approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 2(1):49
5. Al-Salama ZT (2019) Siponimod: first global approval. Drugs 79(9):1009–1015
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod;Journal of Neurology;2023-11-01
2. Emerging strategies for treating autoimmune disorders in patients with type 1 diabetes and multiple sclerosis;INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine);2023-10-31
3. Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies;Inflammatory Bowel Diseases;2023-07-14
4. Recruitment and Residence of Intestinal T Cells – Lessons for Therapy in Inflammatory Bowel Disease;Journal of Crohn's and Colitis;2023-02-20
5. Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge;Neurological Sciences;2023-01-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3